SCHEMBL23852693

SCHEMBL23852693

O=C(Oc1ccc(Cl)nn1)N1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BPTF Q12830 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.35
▸ TPSAB1 Q15661 1/20 0.35
▸ TPSD1 Q9BZJ3 1/20 0.35
▸ TPSG1 Q9NRR2 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ SCN5A Q14524 1/20 0.35
▸ SCN2A Q99250 1/20 0.35
▸ SCN10A Q9Y5Y9 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23851488 0.78 ALDH1A1 (0.48) RXFP1SIGMAR1ALDH1A1POLBLMNA
SCHEMBL30237082 0.77 SIGMAR1 (0.41) RXFP1SIGMAR1ALDH1A1POLBTPSAB1
SCHEMBL23850969 0.75 RXFP1 (0.39) RXFP1SIGMAR1ALDH1A1TPSAB1TPSD1
SCHEMBL17293693 0.75 ALDH1A1 (0.45) RXFP1ALDH1A1POLBTPSAB1TPSD1
SCHEMBL17978906 0.72 HRH3 (0.40) SIGMAR1ALDH1A1TPSAB1TPSD1TPSG1
SCHEMBL26633220 0.72 SCN9A (0.52) SIGMAR1TPSAB1TPSD1TPSG1SCN5A
SCHEMBL25315094 0.72 HRH3 (0.40) SIGMAR1ALDH1A1POLBTPSAB1TPSD1
SCHEMBL18399136 0.72 LMNA (0.36) RXFP1ALDH1A1POLBHSP90AA1LMNA
SCHEMBL27627299 0.72 ALDH1A1 (0.56) ALDH1A1POLBLMNASCN5ASCN2A
SCHEMBL19717800 0.72 SCN7A (0.47) RXFP1SIGMAR1ALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4359403-A1 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BeiGene Switzerland GmbH (CH) 2024-05-01 — — EP disclosed
WO-2022268052-A9 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BEIGENE, LTD. (KY) 2023-08-17 — — WO disclosed
WO-2023125908-A1 DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2023-07-06 — — WO disclosed
WO-2022268052-A1 (R) -GLUTARIMIDE CRBN LIGANDS AND METHODS OF USE BEIGENE, LTD. (KY) 2022-12-29 — — WO disclosed
EP-3883928-A1 GLP-1R AGONISTS AND USES THEREOF Qilu Regor Therapeutics Inc. (CN) 2021-09-29 — — EP disclosed
Send feedback